Copyright: Knowledge Utilization Research Center Chapter 3 How Global Health Research Strengthens Research in Countries Knowledge Utilization Research.

Slides:



Advertisements
Similar presentations
Strengthening the Pharmaceutical Sector: Mechanisms to Monitor Performance Douglas L. Keene June 15, 2010.
Advertisements

Mandate and Terms of Reference of the CEWG. The Presentation Background Mandate from the Resolution Points requiring clarity Resolution WHA63.28.
Consultative expert working group - proposals Barcelona
Summary of 3 rd CEWG meeting by Chair and Vice-Chair Open Session CEWG on R&D Financing and Coordination November 18, 2011.
WIPO Conference on Building Partnerships for Mobilizing Resources for Development Thematic Session 2 Science, Technology and Innovation for Development.
Group 3 Financing EFA: Domestic resource mobilization and external support Facilitator: Robert Prouty, The World Bank.
1 Coordinating and Financing R&D in Developing Countries-moving beyond PDP's The ANDI Experience Solomon Nwaka CEWG on R&D Financing & Coordination, April.
Working Together to Improve Global Health
0 African Network for Drugs & Diagnostics Innovation Dr. Alexander Ochem.
RECOMMENDATIONS BY INTELLECTUAL PROPERTY LAWYERS ON LEGAL REFORM MOSES NKOMO LL.B, MIP.
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
American Evaluation Association EVALUATION 2011 November 3, 2011 Approaches to Biomedical Research and Development Portfolio Analysis: Examples From the.
The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January
PRESENTED BY ELIZABETH TAMALE ASSISTANT COMMISSIONER MINISTRY OF TRADE, INDUSTRY AND COOPERATIVES AID FOR TRADE, INTELLECTUAL PROPERTY AND DEVELOPMENT-
World Health Organization
Public health, innovation and intellectual property 1 |1 | WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Global Strategy and Plan.
Vision: Sustainable development for Cambodia.  Status of civil society  Internal and external demands  Contributions of CCC members to development.
The NIH Roadmap for Medical Research
1 st Meeting of the CEWG 5-7 April, 2011 WHO, Geneva Consultative Expert Working Group R&D: Financing and Coordination Background & Context.
A very short introduction to patents & access to medicines.
Course 17: Neglected Tropical Diseases & NCDs 9 th GA of IAPB Hyderabad; 19 th September 2012 NCDs & Eye Health Converging interests and opportunities.
The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.
At What Cost? U.S. Leadership in Global Health in an Era of Austerity Dr. J. Stephen Morrison Senior Vice President; Director, Global Health Policy Center.
Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.
Some aspects of National STI system in Albania & The Research at Polytechnic University of Tirana T.Korini, UPT, Tirana Tbilisi, 11 April 2012.
1 Who will innovate to meet the health needs of low income populations in developing countries? Joanna Chataway ESRC INNOGEN Centre Dinar Kale ESRC INNOGEN.
Science for Global Health: Fostering International Collaboration Norka Ruiz Bravo,PhD Special Advisor to the Director National Institutes of Health U.S.
WHO Technical Briefing Seminar on Essential Medicines & Health Products, October 2013 Noncommunicable Diseases –Action Plan Dr Shanthi Mendis Director,
Global Leadership in Medical Innovation: “Ours to Lose”
Sources of Support and What They Mean to the Field Dr. Duff Gillespie June 15 th, 2002 Africa SOTA, Nairobi.
The Global Fund- structure, function and evolution February 18, 2008.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
A Health Innovation Systems Approach: The Opportunity and the Challenge Dr. Padmashree Gehl Sampath Department for Public Health, Innovation and Intellectual.
Perspectives on the Sharing of Research Materials and Data Reid Adler Founder and Principal, Practical Innovation Strategy Washington, DC Presentation.
Bridging Gap in Global Innovation – From need to Access, Said Business School, University of Oxford 9-13 September 2007 Strategies for Managing Innovation.
A new start for the Lisbon Strategy Knowledge and innovation for growth.
Improving Access and Quality Use of Medicines in Palliative Care within National Drug Policy, Regulatory, and Funding Frameworks Debra Rowett, Tania Shelby-James,
Key Barriers for the ICT Research Sector in Serbia, and Recommendations for Future EU- Serbia Collaboration Miodrag Ivkovic, ISS Milorad Bjeletic, BOS.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department.
The PHEA Educational Technology Initiative. Project Partners PHEA Foundations – Ford, Carnegie, Kresge, MacArthur South African Institute for Distance.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.
The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
The PHEA Educational Technology Initiative. Project Partners PHEA Foundations – Ford, Carnegie, Kresge, MacArthur South African Institute for Distance.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Fifth Session of the Islamic Conference of Health Ministers Panel Discussion IV: NGO Involvement in the Improvement of Health Services in OIC Member Countries.
Copyright: Knowledge Utilization Research Center Chapter 5 Recommendations-A Road Map to Support Countries in Strengthening National Health Research Systems.
Preliminary classification of proposals by the CEWG Proposals for innovative financing: Discussing the work to-date of WHO’S Consultative Expert Working.
Putting Health in All Policies into Practice Dr Kira Fortune 1 To provide the context of the HiAP Regional Plan of Action 2 To illustrate how the HiAP.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
Knowledge Transfer Accelerating Innovation. slide 1 The Knowledge Transfer Group at the HR Induction Program (session II) 6 th September 2011 Enrico Chesta.
The Global Drug Gap: Access Inequities and Policy Implications Michael R. Reich Harvard School of Public Health International Conference on Pharmacoepidemiology.
Science & Technology for National Progress in African Region: Highlights of Regional Strategy and Action Professor Gabriel B. Ogunmola, FAS President,
Clinical and Translational Science Awards (CTSAs) Future Directions and Opportunities for ACNP investigators.
GLOBAL COOPERATION FOR IP AND DEVELOPMENT Esteban Burrone Head of Policy Medicines Patent Pool.
A Crucial Moment for Scientific Cooperation ESOF-2014 June 25, 2014.
Knowledge for welfare and health National Research and Development Centre for Welfare and Health International Development Collaboration1 Social inclusion.
David M. Murray, Ph.D. Associate Director for Prevention Director, Office of Disease Prevention Multilevel Intervention Research Methodology September.
Science for Global Health: Fostering International Research Collaboration James Herrington, PhD, MPH Director Division of International Relations Fogarty.
Ownership & (intellectual) property rights in publicly funded biobanks - Challenges, Opportunities & Alternatives - 45 min Assoc. Prof. Timo Minssen.
WHO’s prioritised research agenda for the prevention and control of NCDs prioritises
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
GARD/NCD Action Plan & 2011 UN Summit on NCDs
Advancing South-South Cooperation for Effective Implementation of
World Health Organization
Vietnam Investment and Finance for TB
Summary of 3rd CEWG meeting by Chair and Vice-Chair
Presentation transcript:

Copyright: Knowledge Utilization Research Center Chapter 3 How Global Health Research Strengthens Research in Countries Knowledge Utilization Research Center

Copyright: Knowledge Utilization Research Center Dr Reza Majdzadeh Epidemiologist Knowledge Utilization Research Center; Tehran University of Medical Sciences 2 /46

Imbalances- 1  Gaps and imbalances as characterized by the '10/90' where only 10% of resources are spent on research into 90% of the world's health problems.  2:1 ratio in R&D funding allocated to non- communicable diseases (NCDs) and communicable diseases (CDs) respectively. Copyright: Knowledge Utilization Research Center3

Imbalances- 2  USA: Of 2,900 medicines in development in 2008, 750 (25%) of the compounds were cancer drugs, 312 (10%) for heart disease and stroke and 109 (3.7%) for HIV/AIDS.  Within the private not-for-profit sector, noncommunicable diseases are also widely covered by charity funding, while communicable disease funding remains almost exclusively in the realm of private foundations. Copyright: Knowledge Utilization Research Center4

Imbalances- 3  The above findings partially explains the fact that of the 1,556 new drugs developed between , only 21 (1.3%) were for tropical infectious diseases of the developing world.  Research portfolios must be more balanced and should include support not just for generation of new knowledge but for utilization of existing interventions, i.e. 'implementation research' referred to previously. Copyright: Knowledge Utilization Research Center5

Imbalances- 4  A survey of the major health research funders in the UK, for example, found that health services research received only between % of all the research grants awarded. Copyright: Knowledge Utilization Research Center6

Imbalances- 5  WHO spent approximately $215 million on research through its involvement in more than 60 research networks and partnerships. Based on DALYs, it was also estimated that 84% of the funding is in communicable, maternal, perinatal and nutritional diseases (40% of DALYs) and 4% is allocated to noncommunicable diseases (48% of DALYs). Copyright: Knowledge Utilization Research Center7

Imbalances- 7  An imbalance can be seen in the types of research being supported. In a survey of 140 major funders of health research globally, it was shown that most research is being done on developing new interventions rather than research to make better use of existing interventions.  A survey of the major health research funders in the UK, for example, found that health services research received only between % of all the research grants awarded. Copyright: Knowledge Utilization Research Center8

Imbalances- 8 Copyright: Knowledge Utilization Research Center9

Imbalances- 9 Copyright: Knowledge Utilization Research Center10

 Global Strategy and Plan of Action (GSPA) in Public Health, Innovation and Intellectual Property is expected to address such inequities.  Importantly, the GSPA will be implemented; 'transfer of technology', 'application and management of intellectual property (IP)', 'promoting sustainable financing mechanisms' and 'establishing monitoring and reporting systems’. Copyright: Knowledge Utilization Research Center11

 The Consultative Expert Working Group for Innovative Financing of R&D (CEWG) has been convened to make recommendations on some future innovations in the financing of health R&D. It is expected to complete its work in Copyright: Knowledge Utilization Research Center12

 US NIH has recently announced that it is providing a royalty free license for patents on darunavir (an antiretroviral drug) to the Medicines Patent Pool.  This a welcome political statement that the Obama Administration recognizes the importance of a competitive supply of low cost generic medicines in the struggle to make AIDS treatment more sustainable. Copyright: Knowledge Utilization Research Center13

 In another recent example of a partnership to facilitate access to medicines in developing countries, a collaboration between a manufacturer and an NGO successfully provided access to treatment for a life- threatening condition, chronic myeloid leukaemia (CML) to eligible patients in 80 countries worldwide. Copyright: Knowledge Utilization Research Center14

 Trade-Related Aspects of Intellectual Property Rights (TRIPS) Copyright: Knowledge Utilization Research Center15

Gaining public trust I Copyright: Knowledge Utilization Research Center16

 Ten years after the completion of the draft sequence of the of the human genome, and rapid conceptual and technological advances in genomics and DNA sequencing technologies, we have witnessed, for example, the development of biobanks, many of which have been established in developing countries and bring with it complex ethical questions. Copyright: Knowledge Utilization Research Center17

 Other ethical and regulatory challenges are linked with novel cutting edge technologies with important implications for health such as stem cell research, nanotechnology and synthetic biology. As the first patient enters a trial to test the use of stem cells in treating spinal injury, major concerns are also being expressed globally about ethical and regulatory issues around the testing of these relatively unproven medical technology, as well as related areas of human cell and tissue transplantation. Copyright: Knowledge Utilization Research Center18

Copyright: Knowledge Utilization Research Center19

 In July 2002, for example, only 250 peer-reviewed open access journals existed. In 2010 this number has increased to nearly 3000, representing approximately 18% of all journals.  WHO's HINARI initiative, enabling developing country researchers full text access to more than 7,000 journals, has been mentioned previously. Copyright: Knowledge Utilization Research Center20

Copyright: Knowledge Utilization Research Center21

 In 2008, the WHO and the Wellcome Trust initiated discussions about the development of a Code of Conduct on the sharing of data of public health importance. Copyright: Knowledge Utilization Research Center22

Copyright: Knowledge Utilization Research Center23

Copyright: Knowledge Utilization Research Center24

Copyright: Knowledge Utilization Research Center25

Copyright: Knowledge Utilization Research Center26

Copyright: Knowledge Utilization Research Center27

(1) the proliferation of initiatives and the 'dream' of coordination'; (2) overemphasis on new players rather than reforming and strengthening existing institutions; (3) donor influence on priority setting and their lack of accountability; (4) the rhetoric of health (research) systems; (5) going around government; (6) channeling funds through organizations in the developed world; (7) linking health (research) to broader issues affecting human security and development. Copyright: Knowledge Utilization Research Center28

Copyright: Knowledge Utilization Research Center Visit us on Web: nowledge_Utilization_Research _Center